Skip to search formSkip to main contentSkip to account menu

Dexverapamil

Known as: R verapamil, R-Verapamil 
The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein… 
National Institutes of Health

Related topics

Related topics

2 relations
Verapamilcyclophosphamide/dexverapamil/doxorubicin/etoposide/prednisolone/vincristine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2001
Highly Cited
2001
Uptake and efflux of the peptidic delta-opioid receptor agonist [D-penicillamine2,5]-enkephalin at the murine blood–brain barrier by in situ perfusion
1998
1998
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
The purpose of this study is to evaluate whether metastatic breast cancer that has progressed on an anthracycline-containing drug… 
1998
1998
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.
Agents capable of reversing P-glycoprotein-associated multidrug resistance have usually failed to enhance chemotherapy activity… 
Highly Cited
1997
Highly Cited
1997
Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Conventional methods that are used to overcome multidrug resistance (MDR) often involve the coadministration of chemosensitizers… 
Highly Cited
1997
Highly Cited
1997
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Forty-two patients with advanced solid tumors were entered into a dose-finding study of the combination of doxorubicin with the… 
Highly Cited
1996
Highly Cited
1996
Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
PURPOSE We conducted a phase I crossover study of escalating doses of both paclitaxel (Taxol; Bristol-Myers, Squibb, Princeton… 
Highly Cited
1995
Highly Cited
1995
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
PURPOSE Overexpression of the multidrug resistance gene (mdr-1) is present in up to 60% of relapsed lymphomas. To study its role… 
Highly Cited
1995
Highly Cited
1995
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
PURPOSE Dexverapamil is a competitive inhibitor of the P-glycoprotein (Pgp) efflux pump, a potent mechanism of multidrug… 
Highly Cited
1995
Highly Cited
1995
Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
PURPOSE The reduced cardiac toxicity of the dextro-(d-) stereoisomer of verapamil (dexverapamil; Knoll Pharmaceuticals, Whippany… 
1995
1995
Self-association of dexverapamil in aqueous solution.
The pKa and intrinsic solubility of monomeric dexverapamil were determined from its pH-solubility profile to be 8.90 and 6.6 x 10… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)